Select Publications
Conference Abstracts
2022, 'CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 15 - 15, http://dx.doi.org/10.26190/unsworks/28407
,2022, 'POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION', in Kidney International Reports, Elsevier BV, Vol. 7, pp. S8 - S8, http://dx.doi.org/10.1016/j.ekir.2022.01.027
,2021, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial', in Diabetes, Obesity and Metabolism, Vol. 23, pp. 1652 - 1659, http://dx.doi.org/10.1111/dom.14386
,2021, 'Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus', in Metabolism, Elsevier, Vol. 116, pp. 154509, http://dx.doi.org/10.1016/j.metabol.2020.154509
,2020, 'GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)', in NEPHROLOGY, WILEY, Vol. 25, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 11 - 11
,2020, 'VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE', in NEPHROLOGY, WILEY, Vol. 25, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S269 - S269, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600560&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S61 - S62, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, http://dx.doi.org/10.26190/unsworks/27933
,2020, 'Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 1175 - 1175, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106301178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1098-P
,2020, 'CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1336 - 1336, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101381&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1342 - 1342, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1351 - 1351, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, http://dx.doi.org/10.1093/ndt/gfaa142|iii1351
,2020, 'CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1018 - 1018, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1852 - 1852, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101839&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 215 - 215, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979100211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'SUN-119 COMPARING SURVIVAL IN PATIENTS WITH CHRONIC KIDNEY DISEASE ACROSS THREE COUNTRIES - RESULTS FROM THE STUDY OF HEART AND RENAL PROTECTION-EXTENDED REVIEW (SHARP-ER)', in Kidney International Reports, Elsevier BV, Vol. 5, pp. S250 - S250, http://dx.doi.org/10.1016/j.ekir.2020.02.646
,2019, 'Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S341 - S342, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, '1129-P: Association between the Intensity of Diabetes Therapy, Achieved HbA1c, and Persistence', in Diabetes, American Diabetes Association, CA, San Francisco, Vol. 68, presented at 79th Scientific Sessions of the American-Diabetes-Association (ADA), CA, San Francisco, 07 June 2019 - 11 June 2019, http://dx.doi.org/10.2337/db19-1129-p
,2019, '1130-P: Temporal Trends in Pharmacotherapy for Diabetes', in Diabetes, American Diabetes Association, CA, San Francisco, Vol. 68, presented at 79th Scientific Sessions of the American-Diabetes-Association (ADA), CA, San Francisco, 07 June 2019 - 11 June 2019, http://dx.doi.org/10.2337/db19-1130-p
,2018, 'FACTORS ASSOCIATED WITH REGRESSION OF LEFT VENTRICULAR MASS INDEX IN THE ACTIVE DIALYSIS TRIAL', in NEPHROLOGY, WILEY, Vol. 23, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'IMPACT OF DIETARY SODIUM REDUCTION ON ESTIMATED GLOMERULAR FILTRATION RATE IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS', in NEPHROLOGY, WILEY, Vol. 23, pp. 43 - 43, presented at Australian and New Zealand Society of Nephrology., http://dx.doi.org/10.26190/unsworks/28692
,2018, 'IMPACT OF EXTENDED HOURS DIALYSIS ON UTILITY-BASED QUALITY OF LIFE: RESULTS FROM THE ACTIVE DIALYSIS TRIAL', in NEPHROLOGY, WILEY, Vol. 23, pp. 11 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'INFECTION-RELATED HOSPITALISATIONS ACROSS DIFFERENT LEVELS OF KIDNEY FUNCTION: DATA FROM THE EXTEND45 STUDY', in NEPHROLOGY, WILEY, Vol. 23, pp. 40 - 40
,2018, 'KIDNEY FUNCTION, GLUCOSE-LOWERING TREATMENT AND HBA1C LEVELS IN PEOPLE WITH PREVALENT DIABETES: A POPULATION-BASED COHORT STUDY (EXTEND45)', in NEPHROLOGY, WILEY, Vol. 23, pp. 38 - 38
,2018, 'RELATIVE CONTRIBUTIONS TO MAJOR DIALYSIS RANDOMISED CONTROLLED TRIALS FROM TEN GLOBAL REGIONS', in NEPHROLOGY, WILEY, Vol. 23, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'THE QUALITY OF LIFE IMPROVEMENTS ASSOCIATED WITH EXTENDED HOURS DIALYSIS ARE CONSISTENT ACROSS SUBGROUPS', in NEPHROLOGY, WILEY, Vol. 23, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'CARDIOVASCULAR EVENTS IN A LINKED DATA COHORT OF DIALYSIS PATIENTS: IMPACT OF MODALITY AND EVENT DEFINITION', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, DENMARK, Copenhagen, Vol. 33, pp. 211 - 211, presented at 55th Congress of the European-Renal-Association (ERA) and European-Dialysis-and-Transplantation-Association (EDTA), DENMARK, Copenhagen, 24 May 2018 - 27 May 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433059800573&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'PROGNOSTIC SIGNIFICANCE OF LOW LEVEL OF BLOOD GLUCOSE IN SEVERE ACUTE KIDNEY INJURY: A SECONDARY ANALYSIS FROM THE RENAL STUDY', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, DENMARK, Copenhagen, Vol. 33, presented at 55th Congress of the European-Renal-Association (ERA) and European-Dialysis-and-Transplantation-Association (EDTA), DENMARK, Copenhagen, 24 May 2018 - 27 May 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433059801363&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES: A SYSTEMATIC REVIEWAND META-ANALYSIS', in NEPHROLOGY, WILEY-BLACKWELL, Vol. 21, pp. 108 - 108, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, Vol. 54, pp. S442 - S442, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671302285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'NEW MODELS FOR THE PREDICTION OF EARLY AND LATE RENAL EVENTS IN TYPE 2 DIABETES', in NEPHROLOGY, WILEY-BLACKWELL, Vol. 16, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294977600144&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,